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Abstract. Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors through transfusions,
transplants, insect feces in food, and frommother to child duringgestation.Congenital infection couldperpetuateChagas
disease indeﬁnitely, even in countries without vector transmission. An estimated 30% of infected persons will develop
lifelong, potentially fatal, cardiac or digestive complications. Treatment of infantswith benznidazole is highly efﬁcacious in
eliminating infection. This work evaluates the costs of maternal screening and infant testing and treatment of Chagas
disease in the United States. We constructed a decision-analytic model to ﬁnd the lower cost option, comparing costs of
testing and treatment, as needed, for mothers and infants with the lifetime societal costs without testing and the con-
sequent morbidity and mortality due to lack of treatment or late treatment. We found that maternal screening, infant
testing, and treatment of Chagas disease in the United States are cost saving for all rates of congenital transmission
greater than 0.001% and all levels of maternal prevalence above 0.06% compared with no screening program. Newly
approved diagnostics make universal screening cost saving with maternal prevalence as low as 0.008%. The present
value of lifetime societal savings due to screening and treatment is about $634 million saved for every birth year cohort.
The beneﬁts of universal screening for T. cruzi as part of routine prenatal testing far outweigh the programcosts for all U.S.
births.
INTRODUCTION
Chagas disease, also called American trypanosomiasis, is
caused by Trypanosoma cruzi, which is spread by triatomine
insect vectors.1,2 Infected insects are found from southern
South America to the southern states of the United States,
although vector transmission to humans is very rare in the
United States.3–5 Vector control has been very successful in
many endemic regions.1,2,6 Transmission can also occur
through blood transfusions, organ transplantation, con-
sumption of insect feces in food, and from mother to child
during gestation.3 Almost all endemic countries have in-
stituted screening of blood products.1,2 Despite the existence
of domestic and wild animal reservoirs, signiﬁcant progress in
reducing incidence is possible through rigorous domestic
vector control and screening of blood and organ donors.1
Congenital transmission, on the other hand, could perpetuate
the existence of Chagas disease indeﬁnitely, even in countries
or regions with no or almost no autochthonous vector
transmission.7–10 This article uses a decision-analytic model
to evaluate the societal economic cost of maternal screening
to identify and treat infected newborns and their mothers
compared with the societal cost of undiagnosed or late-
diagnosed Chagas disease in the United States.
Prevalence. The World Health Organization estimates that
there are 5.7 million people infected with T. cruzi in Latin
America1 and about 400,000 Latin Americans with Chagas
disease residing in Europe, Japan, and theUnited States.4,6,11
Successful programs in domestic and peridomestic vector
control reduced the estimated number of new cases from
700,000 per year in the 1970s to 40,000 per year in 2010.1,6
Vector transmission has been the predominantmode, butwith
control programs and blood bank screening, incidence is
decreasing. Congenital transmission, however, accounts for
9,000 new cases per year in Central and South America1 and
several hundredmore in theUnitedStates andEurope.4,12 The
Pan American Health Organization estimates that a quarter of
new cases are caused by congenital transmission.7,13
Nature of the disease. Chagas disease has two stages—
acute and chronic.2,6,14 In the acute phase, most newly infected
persons, including children infected by insect vectors and in-
fants infected congenitally, are asymptomatic or display non-
speciﬁc symptoms.6,14 Infants with congenital infection may
presentwith fever, anemia, and lowApgar scores—symptoms
that can lead to misdiagnosis at birth of toxoplasmosis, ru-
bella, or cytomegalovirus.6,10,15 In a small number of cases,
congenitally infected infants will have severe symptoms, in-
cluding meningoencephalitis, gastrointestinal complications,
and respiratory distress.3,15,16 In most newly infected persons,
the acute phase lasts 4–12weeks, duringwhich parasitemia
is high.3,6
Following the acute phase, infected persons enter the in-
determinate form of chronic phase infection, which can last
10–30 years or an entire lifetime.3,6 Precisely deﬁned, persons
with the indeterminate form of chronic Chagas disease have
“positive anti-T cruzi serology, no symptoms or physical ex-
amination abnormalities, normal 12-lead electrocardiogram
(ECG) ﬁndings, and normal ﬁndings on radiological examina-
tion of the chest, esophagus, and colon” (page 2172),14 see
also ref. 6. An estimated 60–70% of infected persons will re-
main in this form for the rest of their lives and will have normal
life expectancy.6
The proportion of chronically infected persons who will
begin to show symptoms, that is, enter the chronic de-
terminate form, has been estimated from 30% to 40%, gen-
erally from 10 to 30 years after infection.1,6 Symptoms can be
mild and may not be identiﬁed as Chagas related. For some,
however, the ﬁrst recognized sign of Chagas disease is sud-
den cardiac death.6 Chagas disease is the leading cause of
heart disease among persons living in poverty in Latin Amer-
ica.13 Cardiovascular symptoms of Chagas disease include
conduction system abnormalities, arrhythmias, and heart
failure.14 Digestive symptoms of Chagas disease occur less
often and include megacolon and megaesophagus.6 Chagas
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disease has the highest disease burden of all parasitic dis-
eases in the Americas,2 and the human cost of premature
death and disability due to Chagas disease is substantial. The
economic cost of Chagas disease is also high, including
the loss of workers through death and disability, as well as the
costs of medical interventions for cardiac and digestive pa-
thology. One of the few studies of the economic cost of
Chagas disease in Latin America estimated it to be in excess
of U.S. $6.5 billion annually, although that was reported in
the 1990s, when prevalence was higher.17
Chemotherapeutic treatment. Currently, two drugs,
benznidazole and nifurtimox, are used to treat Chagas dis-
ease. In August 2017, benznidazole was approved by the U.S.
Food and Drug Administration (FDA) for use in children aged
2–12 years, but as of February 2018, it was not yet available in
U.S. pharmacies. Asof February 2018, nifurtimoxwasnot FDA
approved. Both drugs are currently available under in-
vestigational protocols from the Centers for Disease Control
and Prevention (CDC).14 Efﬁcacy and side effects vary,
depending on the age of the person and the length of time
since infection.3,18 Treatment of infants before the age of
1 year is 90–100% effective in eliminating infection.12,14 Esti-
mates of efﬁcacy of treatment of adults range from 40% to
70%.12 There is evidence that treating women before preg-
nancy can reduce the risk of congenital transmission.19,20
Treatment has not been shown to reverse cardiac or digestive
tract damage among infected persons who already have
complications.21
Chagas disease in theUnited States.Based on estimates
from the U.S. CDC, there are about 300,000 persons with
Chagas disease in the United States, the majority of whom
were infected in endemic countries before residing in the
United States.4 Based on the number of women of child-
bearing age in that population, the birth rate, and the risk of
maternal transmission, there are an estimated 63‒315 births
of infected infants per year.4 There are some local data for
pregnant women and newborns. In Texas, among 4,000
women who came for delivery at a Houston hospital serving a
mostly immigrant population, 0.25% of mothers had Chagas
disease.22 Another study found that 0.4% of Hispanic women
tested in Houston clinics were infected with T. cruzi.23
Chagas disease is also transmitted in the United States by
insect vectors. A few cases of autochthonous transmission
havebeen reported in theUnitedStates.5,24 In studiesof blood
donors, persons with antibody to T. cruzi and no history of
residence outside the United States have been identiﬁed.25
Maternal screening to identify Chagas-infected infants,
mothers, and siblings. Screening of pregnant women and
newborns is an accepted protocol for preventing or managing a
number of diseases that can be transmitted congenitally, in-
cluding syphilis, human immunodeﬁciency virus (HIV), and in
someplaces, toxoplasmosis, rubella, andcytomegalovirus.8,22,23
There are as many as 80 newborn screening tests available in
some U.S. states, primarily for genetic disorders, but also
including also congenital toxoplasmosis and HIV (http://
www.babysﬁrsttest.org/newborn-screening/states).
Because complications in the chronic stage of Chagas
disease are associated with long duration of infection,6 early
diagnosis and treatment are essential not only for newborns
but also for their mothers, siblings, and other family members.
Pregnant women and babies present a good access point for
diagnosing and treating the whole family because prenatal
checks and hospital births may afford the greatest likelihood
over the lifetime of identifying the affected population, par-
ticularly among people who may be reluctant to seek medical
attention.
At present, there is no systematic screening for Chagas
disease in pregnant women in the United States. Surveys of
obstetricians indicate that few are well informed about the risk
ofChagas disease, even thosewho attend toHispanicwomen
fromendemic areas.26 Effective screening for Chagas disease
would require educating prenatal and delivery care personnel.
The concentration of Chagas disease in ﬁrst- and second-
generation Latinos from endemic countries and in nonmi-
grants residing in speciﬁc parts of the United States suggests
that targeted screening would be more efﬁcient in terms of
cost, education of obstetricians, and minimizing distress for
mothers. On the other hand, targeting may be difﬁcult for cli-
nicians and it might be more feasible to include T. cruzi in
routine screening protocols for all pregnant women.
A protocol for screening could be established as follows:
before or during pregnancy or at birth, women would be
offered serologic testing, preferably using a serologic rapid
test for antibody to T. cruzi, to obtain immediate results.2,14
Women with positive rapid antibody test results would be
further tested to conﬁrm infection. Babies born to infected
mothers would be tested at birth (cord blood) and, if negative,
again at 4‒6 weeks of life by polymerase chain reaction (PCR)
testing,which is the recommended approach for U.S. testing.14
(In Latin America, the practice is generally examination of blood
smear and/or microhematocrit concentration method.27) Be-
cause of varying levels of parasitemia in congenital infection,
infants with negative results would be tested by serology at
9 months of age or older, after maternal antibody is no longer
present.2,3 Infected infants would be treated with benznida-
zole or nifurtimox. Infected mothers would potentially be
treated, after ending breastfeeding.14,15 Older children of in-
fected mothers would also be tested and treated, if infected.
Ideally, other infected family members, such as siblings of the
mother, could be identiﬁed for treatment and follow-up.
Economic evaluation of maternal screening. There have
been few studies of the economic cost of Chagas disease and
of interventions to reducemorbidity andmortality. Even fewer
are the economic evaluations of maternal screening pro-
grams. Sicuri and others estimated the costs of a systematic
screening program for Latin American women in Spain. They
used two decision trees, one for the costs for mothers and
another for the costs for infants. They found that a screening
program was cost-effective over a broad range of screening
costs andprobabilities ofmaternal prevalence andmother-to-
child transmission.12
METHOD
We compared the costs of maternal screening and infant
testing and treatment as needed (referred to as the Screening
option), with the costs of No Screening, with its consequent
morbidity and mortality due to lack of treatment or late treat-
ment, using one tree that shows the combined costs for each
possible maternal–child pairing. We constructed a decision-
analytic model for the United States using TreeAge software
(TreeAge Software Inc., Williamstown, MA) to ﬁnd the lower
cost option. Themethod is the samewhether one is evaluating
a targeted or a universal screening program because costs
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and beneﬁts (cost savings) are reported on an individual basis.
In the Discussion, we compare the implementation costs and
beneﬁts for targeted and universal screening.
The tree comprises a decision node (No Screening or
Screening), chance nodes (probabilities of maternal infection,
transmission, and various degrees of injury), and terminal
nodes for each outcome (sums of costs attributable to each
outcome). We use a societal perspective. Each outcome
represents the expected value of all economic costs based on
a series of conditional probabilities for each branch.
Probabilities. Table 1 shows the probabilities of maternal
infection (prevalence among women of childbearing age),
maternal transmission, conversion from indeterminate form to
symptomatic form, and other risks of morbidity and mortality.
Point estimates and ranges are derived from the literature in-
dicated in the source column. For prevalence, the point esti-
mate (0.0131) refers to the population of U.S. Hispanicwomen
from endemic areas,4 which is appropriate for a model of
targeted screening. The range, used in sensitivity analysis
(0.0‒0.0131), includes the prevalence among all U.S. women
(0.0016), and is thus appropriate for universal screening.
In a decision analysis, probabilities are conditional on prior
probabilities. For each category, the possibilities are ex-
haustive (sum to 1.0) and mutually exclusive. For example, as
seen in Table1, of persons infectedwithChagasdisease, 30%
are estimated to have symptoms, of whom about 2/3 will have
cardiac symptoms. Similarly, Table 1 indicates that 10% of
infected infants are estimated to be symptomatic at birth,
and the expected distribution of severity of symptoms among
that 10% is given in the subsequent rows of Table 1. The
Supplemental Text contains detailed explanation of the
derivations and sources.
Costs. Table 2 lists all of the unit costs used in the decision
tree, including costs of testing and chemotherapy for infants
and mothers, costs of hospital care for symptomatic new-
borns, and costs of interventions for cardiac and digestive
tract morbidity. The Supplemental Text contains detailed ex-
planation of the cost derivations and sources.
Table 3 lists the present value of lifetime costs of typical
protocols for possible outcomes, including the indeterminate
form and cardiac and digestive complications of the chronic
stage, including productivity losses due to prematuremortality.
The Supplemental Text contains detailed explanation of the
protocols, cost derivations, and sources.
We do not include intangible costs, such as pain or worry,
nor do we include the lost time of family care givers or in-
cidental costs, such as transportation.
The decision tree. The decision tree, Supplemental
Figure 1, is available online and shows the probabilities and
cost formulas pertaining to each possible outcome. It begins
on the left with the decision, No Screening or Screening. In
both branches, mothers have the same risk of infection, which
is based on the estimated prevalence among Hispanics from
endemic countries in theU.S. population4 and the same risk of
gestational transmission to the child, based on a range of
estimates in endemic and non-endemic locations.6,16,28
In the No Screening branch, we assume that mothers who
deliver asymptomatic babies and the babies themselves will
not be identiﬁedasbeingT. cruzi infected, even if they develop
adigestive or cardiac condition that requiresmedical attention
at some point in their lives. On the other hand, the birth of a
symptomatic baby in the No Screening scenario generates a
series of actions that are equivalent to the Screening sce-
nario. Even if those symptoms are mild, we assume the best
practice—that the baby will be diagnosed with Chagas dis-
ease at birth, themother’sChagas diseasewill be diagnosed,
and both will be treated. Each terminal node (at the right)
shows the costs incurred for both the mother and child in a
mother–child pair.
In the Screening branch, before or during pregnancy or at
birth, women would be offered serologic testing, preferably
using a serologic rapid test for antibody to T. cruzi, to obtain
immediate results.2,14 Women with positive rapid antibody
test results would be further tested to conﬁrm infection.
Babies born to infectedmothers would be tested at birth (cord
blood). Infected infants would be treated with benznidazole or
nifurtimox. Infectedmotherswouldpotentially be treated, after
ending breastfeeding.14,15 (Negative results in infants of in-
fected mothers are discussed previously in the protocol.)
The decision tree calculates the cost of each possible out-
come (indicated at each terminal node) multiplied by its con-
ditional probability (along each branch), which determines the
expected value of each possible mother–child outcome (in
U.S. dollars). When comparing the option of Screening to No
TABLE 1
Probabilities
Nodes Name in tree Probabilities Point estimate (range) Sources point estimate (range)
2, 85 Prevalence Maternal prevalence 0.0131 (0–0.0131) 4 (22,23,36)
4, 87 MTCT MTCT 0.05 (0–0.05) 6,16,28 (3,8,15,36,37)
5, 42, 43, 52, 61, 69, 77 SymptomChagas Risk of symptomatic Chagas 0.30 (0.2‒0.4) 13,38,39 (3,6,12,17,40–46)
7, 18, 27, 36, 45, 51, 54, 63, 71, 79,
91, 102, 111, 120, 129
Cardiac Of which cardiac 0.67 (0.67‒0.75) 6,45,47 (40)
# Of which digestive 0.33 (0.25‒0.33) 6,45,47 (40)
9, 20, 29, 38, 47, 56, 60, 65, 73, 81,
93, 104, 113, 122, 131
CardiacMild Cardiac mild 0.4 (0.36‒0.44) 48
CardiacSevere Cardiac severe 0.3 21
# Cardiac very severe 0.3 21
13, 97 SymptomAtBirth Risk of baby symptomatic at birth 0.1 16,29
14, 98 SymptomAtBirthMild Mild symptomatic at birth 0.5 16
SymptomAtBirthSevere Severe symptom at birth 0.45 16
# Neonatal death 0.05 3,6,17,49
15, 24, 33, 88, 99, 108, 117, 126 MotherCured Treated mother cured 0.6 (0.4‒0.7) 3,12 (12)
# (1-MotherCured) ×
(1-SymptomChagas)
0.28 6
MotherSymptomAfterRx (1-MotherCured) ×
SymptomChagas
0.12 (0.06‒0.24) 6
MTCT = mother-to-child transmission.
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Screening, the decision with a lower expected value for life-
time costs for all possible outcomes is selected as the domi-
nant (lower cost) option.
Although the point estimates are set for targeted screening
at current screening cost of $60per pregnancy, themodel also
calculates the costs for universal screening and screening
cost as low as $8 per pregnancy through sensitivity analysis.
Sensitivity analysis. Published studies of Chagas disease
report a range of values for the model’s parameters. We have
chosen conservative values—ones that seem to represent a
consensus among researchers—and we used sensitivity
analysis to test the robustness of the results. We derived the
range of values for four of the clinical probabilities used in the
sensitivity analysis from evidence in the literature: risk of
symptomatic Chagas (0.2–0.4), proportion of symptomatic
Chagas that is cardiac (0.67–0.75), with the residual in that
casebeingdigestive symptoms (0.25–0.33), and the likelihood
of cure among adults after the acute phase (0.4–0.7). These
TABLE 2
Unit costs
Item (name in tree) Unit cost in 2016 Source
Infant PCR × 2 (Dx_baby) $400 http://www.parasitic.com/test.htm
Adult ELISA + IFA (Dx_mom) $60 https://ncifrederick.cancer.gov/programs/science/csp/ltsELISA.asp
https://www.scienceexchange.com/services/immunoﬂuorescence
http://www.abcam.com/chagas-igg-elisa-kit-ab178637.html
https://tvmdl.tamu.edu/?s=Chagas&species=&post_type=tests&
test-submit=Search+Tests
https://www.biocompare.com/pfu/110627/soids/2-399758/
ELISA_Kit/ELISA_Trypanosoma_cruzi
Benznidazole, baby,mom (Rx_baby,Rx_mom) $0 Available without cost from CDC
General practitioner examination, biennial* $166 http://meps.ahrq.gov/mepsweb/data_ﬁles/publications/st484/
stat484.shtml
Cardiologist examination, annual* $303 http://meps.ahrq.gov/mepsweb/data_ﬁles/publications/st484/
stat484.shtml
ECG + stress test, annual or biennial* $220 Federal Register 81(219) Nov 14, 2016, page 79724 https://www.gpo.
gov/fdsys/pkg/FR-2016-11-14/pdf/2016-26515.pdf
Amiodarone, ﬁrst year $425 http://reference.medscape.com/drug/pacerone-cordarone-
amiodarone-342296Annual* $100
https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2017-01-18/
e97y-sprb
Pacemaker* $22,230 http://medicarehelp.org/cost-of-medicare/procedure/state/
Maryland
Heart transplant* $942,830 http://www.milliman.com/uploadedFiles/insight/Research/health-rr/
1938HDP_20141230.pdf
Gastroenterologist, annual* $310 http://meps.ahrq.gov/mepsweb/data_ﬁles/publications/st484/
stat484.shtml
Esophageal relaxants, annual* $160 http://www.mayoclinic.org/diseases-conditions/esophageal-
spasms/basics/treatment/con-20025653
https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2017-01-18/
e97y-sprb
Laxatives, annual* $33 https://www.drugs.com/pro/docusate-sodium.html
https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2017-01-18/
e97y-sprb
Fundoplication* $11,234 http://www.medicarehelp.org
Colon resection* $44,718 http://www.medicarehelp.org
Neonatal hospital costs, mild symptoms
(CostSympMild)
$2,600 https://www.hcup-us.ahrq.gov/reports/statbriefs/sb113.pdf
Neonatal hospital costs, severe symptoms*
(CostSympSev)
$3,900 https://www.hcup-us.ahrq.gov/reports/statbriefs/sb113.pdf
CDC = Centers for Disease Control and Prevention; ECG = electrocardiogram. See Supplement Text for detailed cost derivations; ELISA = enzyme-linked immunosorbent assay; IFA =
immunoﬂuorescence assay.
* Part of indeterminate, cardiac, or digestive package (see Table 3 and Supplemental Table 3).
TABLE 3
Conditions and package costs (present value)
Condition
Mothers with Trypanosoma cruzi
diagnosis
Mothers without T. cruzi
diagnosis
Babies as adults without
diagnosis
Chronic, indeterminate $5,495 No treatment No treatment
Chronic cardiac, mild $106,938 $112,095 $39,929
Chronic cardiac, severe $407,315 $414,519 $146,015
Chronic cardiac, very severe $1,893,955 $1,905,848 $723,246
Esophageal, mild $115,367 $109,727 $39,016
Esophageal, severe $390,998 $387,771 $139,749
Colon, mild $112,383 $105,952 $37,514
Colon, severe $435,716 $433,861 $154,109
Digestive care costs, average of
digestive conditions
$263,616 $259,328 $92,597
SeeSupplementText for detailedprotocols andcost derivations for eachcondition.Amounts inbolded text are used in thedecision tree.Unbolded text indicates intermediate calculations used to
derive digestive care costs.
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rangesare listed inTable 1, column4, in parentheses, and their
respective sources are shown in Table 1, column 5, in pa-
rentheses. For the other variables in Table 1, since they do not
have a range reported in published literature, we used ±10%.
The cost saving from a maternal screening program can be
expected to be especially sensitive to two clinical variables:
prevalence among pregnant women and mother-to-child
transmission risk. It is argued by some that mother-to-child
transmission should be lower in the United States than in
highly endemic areas because reinfection in the latter areas
increases parasitemia and transmission risk.29 On the other
hand, higher parasitemia and higher transmission risk have
been reported among mothers not exposed to reinfection,
possibly because of loss of immunity.27 For both prevalence
and maternal transmission, we set zero as the lower bound
and set the point estimate as the upper bound, as shown in
Table 1.
Costs and cost-to-charge ratios can vary greatly across the
country and across payers. Consequently, we used sensitivity
analysis to test the robustness of our results to differences in
treatment costs for indeterminate, cardiac, and digestive Cha-
gas outcomes, treatment costs for symptomatic newborns, and
productivity losses pertaining to the various health states. We
used±10%for theupperand lowerbounds foreachof thecosts.
In a screening program for a low-prevalence population, how-
ever, thecostof testingcanbeespecially important.Whereaswe
use the testing cost of $60 for thematernal test ($30 × 2 tests), a
new point-of-care diagnostic was approved by FDA in Decem-
ber 2016 for which the expected price will be $4.00.30,31 For the
sensitivity analysis, we set $4 per test as the lower bound ($8 for
two tests) and$30per test ($60 for two tests) as theupperbound
to determine the threshold maternal prevalence for which
screening is cost saving and the amount of savings under a
range of scenarios.
Another form of sensitivity analysis is tornado analysis,
which indicates the factors that have the greatest impact on
total costs, showing the variation around the expected value
for the Screening or No Screening option that results from
varying each parameter. An incremental tornado analysis
combines the information for both options and determines
how the expected value of savings varies because of differ-
ences in each parameter. We use the incremental tornado
analysis to show the factors that have the greatest impact on
expected lifetime savings.
RESULTS
Supplemental Figure 2, available online, shows the decision
tree after calculation. The analysis concluded that Screening
is the optimal option. If no screening takes place, the expected
value of discounted lifetime costs for all mother–child pairs is
$2,321 per pregnancy. The Screening option has an expected
cost for infant and mother of $997 per pregnancy. Screening
would result in a saving of $1,324 per birth or $636 million for
each birth year cohort of 480,000 births to women from en-
demic areas. These results correspond to the savings per birth
in a targeted screening program, using prevalence of 0.0131
among Hispanic women from endemic areas. Table 4 dis-
plays these results. This ﬁnding lends substantial economic
support to a policy of educating obstetricians in the United
States and adding maternal screening for Chagas disease to
the panel of tests for Hispanic women who themselves or
whose mothers lived in endemic areas. (For a description of
how costs are calculated for an individual mother–child pair,
see Supplemental Text.)
Sensitivity analyses.Whereas the point estimates refer to
a targeted strategy, the same model demonstrates that uni-
versal Screening is also cost saving compared with No
Screening at the current screening cost of $60 per pregnancy.
The threshold prevalence for which screening is cost saving is
0.0005678, or 0.06%, as shown in Figure 1. The estimated
prevalence of T. cruzi infection among all 4 million women
giving birth per year in the United States is 0.001575, or
0.16%. The savings per birth are lower at lower prevalence but
they are still substantial for universal screening. The lifetime
costs per birth in the No Screening scenario are $279, and in
the universal Screening scenario at thematernal prevalence of
0.16% (estimated U.S. prevalence) and $60 screening cost,
lifetime costs are $173per birth,with savings per birth at $106.
For 4 million births annually, that amounts to total savings of
$426 million for every birth year cohort.
Availability of a low-cost point-of-care testmakes screening
an even more viable option. Using $4 per test (× 2 tests = $8
per birth) for maternal diagnosis, we performed a one-way
sensitivity analysis on maternal prevalence. At that test cost,
the threshold for screening as the cost saving option is ma-
ternal prevalence of 0.0000757 (0.008%). In the targeted
Screening scenario, savings per birth are $1,376 and total
savings for the birth year cohort amount to $660 million.
To get a more detailed look at costs and savings in a uni-
versal screening scenario, we show the results of a two-way
sensitivity analysis, varying prevalence from 0.0 to 0.001575,
the estimated prevalence among all U.S.women in a birth year
cohort, and varying the screening cost from$8 per birth to $60
per birth. Table 5 shows the results with ﬁve intervals for each
parameter. At any screening cost below $40 per birth, the
Screening option is cost saving for any nonzero prevalence
shown as low as 0.00032, which is 1/5 the actual estimated
prevalence among all womengiving birth annually in theUnited
States (all non-bolded results). As seen also in Figure 1, uni-
versal screening is cost-saving even at $60 per mother, even if
national prevalence were far below present estimates.
The expected value of the lifetime savings from universal
screening with the new point-of-care test (at $8 per birth) is
$158 per birth, amounting to $634 million for each birth year
cohort, as shown in Table 4. The sensitivity analysis demon-
strates that universal screening is cost saving over a wide
range of prevalence and screening costs in the United States.
Incremental tornado analysis. Figure 2 shows the in-
cremental tornado analysis diagram, assuming a $60
TABLE 4
Results: lifetime societal costs and savings for No Screening and
Screening
Scenario
$60 screening cost per birth $8 screening cost per birth
Per birth Per birth year cohort Per birth Per birth year cohort
Targeted Screening
No Screening $2,321 $1,114,080,000 $2,321 $1,114,080,000
Screening $997 $478,560,000 $945 $453,600,000
Savings $1,324 $635,520,000 $1,376 $660,480,000
Universal Screening
No Screening $279 $1,116,400,000 $279 $1,116,400,000
Screening $172 $690,640,000 $121 $482,640,000
Savings $106 $425,760,000 $158 $633,760,000
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maternal diagnosis cost. The expected value of lifetime
savings per birth indicated on the x axis is $1,324. The
horizontal bars show, in descending order, themagnitude of
the effect of changing the parameter values. Clearly, the
only parameter that makes an important difference in the
savings from the Screening option is maternal prevalence.
Althoughwe had anticipated that variation in themother-to-
child transmission rate would have an appreciable effect, it
did not. Varying mother-to-child transmission from 0.0 to
0.05 had a trivial effect on the estimate of savings, ranking
13th among parameters and barely visible in Figure 2. Thus,
even if maternal transmission is extremely low in the United
States because of environmental or biological factors, it
makes little difference in the large savings from screening.
Maternal screening costs also had little impact on total
costs.
A parameter that had a nontrivial effect on cost savings was
the proportion of treated mothers who are not cured and be-
come symptomatic. In the worst case scenario, with the
highest probability of no cure (0.6) and the highest probability
of being symptomatic (0.4), 24% of mothers face cardiac or
digestive morbidity despite treatment. This combination af-
fects both options, but, even so, savings per birth from the
Screening option do not fall below $400.
FIGURE 1. One-way sensitivity analysis on maternal prevalence, showing threshold. This ﬁgure appears in color at www.ajtmh.org.
TABLE 5
Comparison of lifetime costs per birth by prevalence and screening cost
Screening cost per birth
$8.00 $18.40 $28.80 $39.20 $49.60 $60.00
Prevalence Lifetime costs per birth by prevalence and screening cost (U.S. $)
0.0 No Screening 0.00 0.00 0.00 0.00 0.00 0.00
Screening 8.00 18.40 28.80 39.20 49.60 60.00
Saving −8.00 −18.40 −28.80 −39.20 −49.60 −60.00
0.000315 No Screening 55.82 55.82 55.82 55.82 55.82 55.82
Screening 30.53 40.93 51.33 51.33 72.13 82.53
Saving 25.29 14.89 4.49 4.49 −16.31 −26.71
0.00063 No Screening 111.64 111.64 111.64 111.64 111.64 111.64
Screening 53.06 63.46 73.86 84.26 94.66 105.06
Saving 58.58 48.18 37.78 27.38 16.98 6.58
0.000945 No Screening 167.46 167.46 167.46 167.46 167.46 167.46
Screening 75.60 86.00 96.40 106.80 117.20 127.60
Saving 91.87 81.47 71.07 60.67 50.27 39.87
0.00126 No Screening 223.28 223.28 223.28 223.28 223.28 223.28
Screening 98.13 108.53 118.93 129.33 139.73 150.13
Saving 125.16 114.76 104.36 93.96 83.56 73.16
0.001575 No Screening 279.10 279.10 279.10 279.10 279.10 279.10
Screening 120.66 131.06 141.46 151.86 162.26 172.66
Saving 158.45 148.05 137.65 127.25 116.85 106.45
Numbers in italic are savings per birth. Numbers in bold italic are negative savings per birth (losses).
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DISCUSSION
This decision analysis evaluated the lifetime societal costs
and beneﬁts of screening during pregnancy or at delivery for
T. cruzi infectionwith the goal of treating infectedmothers and
infants to reduce or eliminate the risk of symptomatic Chagas
disease. Those costs and beneﬁts were compared with the
lifetime costs of undiagnosed or late-diagnosed Chagas dis-
ease thatwould result fromnot screeningmothers and infants.
The results of the decision analysis demonstrate that the
expectedvalue, or per-birth cost, of theNoScreeningoption is
greater, generally substantially greater, than for the Screening
option, over a broad range of screening costs and estimated
prevalence. The total savings per birth year cohort of universal
screening range from $426 to $634 million, for screening cost
ranging from $60 to $8 per birth. We have not calculated the
additional beneﬁts of testing siblings and other family mem-
bers. Those beneﬁts, however, would amplify the results of
this cost analysis.
There are an estimated 300,000 persons in the United
States with Chagas disease.4 Using the standard estimation
of the likelihood of developing symptoms (0.3), we could ex-
pect as many as 90,000 persons to develop cardiac or di-
gestive symptoms out of the current population of infected
persons in the United States. In the present analysis, we are
estimating only the costs for pregnant women and their cur-
rent pregnancy. The 63–315 infected infants born per year, if
undiagnosedanduntreated, face a30%chanceof developing
disease symptoms. Thus, we can expect between 19 and 95
infants to develop cardiac or digestive symptoms of Chagas
disease. Similarly, there would be 6,300 infected mothers
giving birth each year, of whom 1,890 would be expected to
develop cardiac or digestive symptoms of Chagas disease.
These symptomatic infections in mothers and children are the
source of more than $1 billion in lifetime costs of undiagnosed
and untreated Chagas disease for each birth year cohort (see
Table 4).
Cost of the screeningprogram.The implementation costs
of the screening program are far less than the costs attributed
to the Screening scenario because that scenario includes the
costs of cardiac and digestive symptoms of mothers who
are diagnosed and treated butwho are not cured (referred to in
the section on incremental tornado analysis). Those costs for
symptoms would result anyway in the No Screening scenario.
The costs of the T. cruzi screening program alone would
consist of testing for mothers, testing babies of infected
mothers at birth, treating infected mothers and babies, and
some additional cardiac monitoring for mothers in the in-
determinate phase or with digestive conditions who are di-
agnosed as a result of the screening program but would not
have been diagnosed under the No Screening scenario. The
implementation cost of the screening program is shown in
Table 6 for both targeted and universal screening at $60 and
$8 screening cost. Universal screening at the new test cost
would amount to about $66 million, about half of which is the
screening cost and about half represents the costs of en-
hanced care for women with digestive or indeterminate con-
ditions who would not have been identiﬁed in the No
Screening scenario. The beneﬁt ($634 million, the discounted
present valueof thesavings) is thusalmost 10 times thecost of
the screening program for each birth year cohort.
Targeted versus universal screening. The decision be-
tween a targeted screening program and a universal program
has ﬁnancial implications, but logistical considerations may
be paramount. A targeted program imposes an additional
burden on obstetricians who would have to identify women
from endemic areas among their patients. Proﬁling based on
last name or other characteristic is unreliable and inappropriate,
and so, doctors and physicians’ assistants would have to
FIGURE 2. Incremental tornado analysis diagram. This ﬁgure appears in color at www.ajtmh.org.
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question new patients about the place of origin. Such an
inquiry could make patients reluctant to seek prenatal care.
Universal prenatal and newborn screening is routine across
the United States for numerous low-prevalence conditions,
although the menu of tests may differ from state to state. HIV
testing of pregnant women or newborns is routine in many
states and has even been mandatory in some states. An es-
timated 8,500 HIV-infected women give birth each year,
compared with an estimated 6,300 women with T. cruzi in-
fection. Thesimplest strategy is universal screening forT. cruzi
during prenatal care or at birth, even thoughwe know that only
about 12%of pregnantwomenare at risk. Universal screening
is cost saving even at $60 per woman screened, but the new
point-of-care test makes universal screening easier and more
cost saving.
Limitations. Conservative use of the decision tree meth-
odology, which we have followed, tends to underestimate
the costs of the No Screening scenario, overestimate the
costs of the Screening scenario, and thus underestimate the
net savings of Screening. We are comparing No Screening to
Screening, both with best practice in follow-up care in iden-
tiﬁed persons. That is, we assign costs to all cases discovered
as if they would get pacemakers, transplants, annual cardi-
ology checkups, or whatever the best care available would be.
In the case of identiﬁed indeterminate chronic Chagas dis-
ease, for example, we assign the costs of biennial cardiology
checkups formothers up to age of life expectancy of 84 years.
It is likely that many of the womenwould have stopped having
biennial checkups after many years of good results.
The assumption that, without screening, symptomatic infants
will be correctly diagnosed at birth, and that infected mothers
and infants will be treated according to best practice, may be
overly optimistic. Moreover, our estimate that 10% of infected
newbornswill besymptomaticmaybehigh for theUnitedStates.
Thus, in themodel, all of these assumptions lead to substantially
lower costs in the No Screening scenario. Consequently, the
savings from Screening are understated in the results.
Ideally, in the Screening scenario, infants with negative test
results born to infected mothers would be retested at
9months of age, but loss to follow-up could reduce the impact
of the program. Of course, the proportion of undiagnosed and
untreated infants would still be far higher in the No Screening
scenario because only infants symptomatic at birth would be
diagnosed and treated.
For low-prevalence conditions, when diagnostic tests
have < 100% speciﬁcity, the number of false positives could
far exceed the true positives. This would be especially true
with universal screening among the approximately 3.5 million
womenwith almost no likelihood of exposure to infection. The
new diagnostics, which would be suitable for universal
screening, are reported in ﬁeld trials to have 98.8% speciﬁcity
inwhole bloodand96.9% in serum.30 If actual speciﬁcity in the
U.S. setting, for example, is 96%, thenumber of falsepositives
among all 4 million births would be about 160,000. Some
physicians, on consultationwith themother,might dismiss the
results, but many would send them for conﬁrmatory testing,
which would increase costs. The estimated additional cost
could be as high as $9.6 million, which although substantial,
adds less than 15% to screening costs per se and reduces the
savings from Screening versus No Screening by 1.5%, from
$634 to $624 million per birth year cohort.
For comparison, rapid diagnostic tests (RDTs) for HIV are
reported to have 99% speciﬁcity,32,33 but at least one RDT
(First Response) had 100% speciﬁcity on whole blood but
82.86% speciﬁcity with serum specimen for HIV-1.34 Com-
paring results with serum specimen, the HIV test would gen-
erate farmore false positives than theChagasRDTwith serum
that was used for estimating cost stated earlier.
The decision analysis reports the costs and beneﬁts (costs
avoided) for each complete scenario. In the Screening sce-
nario, all infected mothers would be treated, but only 60% of
them would be cured. The medical costs and productivity
losses from their Chagas symptoms are assigned to the
Screening scenario, but those symptoms and costs would
have occurred if thewomen had not been screened and a cure
attempted. They are not a result of the Screening protocol but
rather occur despite it.
We underestimate the savings of the Screening option be-
cause we do not include the savings for subsequent preg-
nancies for mothers treated as a result of screening.
Another factor is the lowlevelofmedicalcoverageofHispanics
in the United States, but the overestimation of access to care
affects both scenarios. “In 2016, non-Hispanic Whites had the
lowest uninsured rate among race andHispanic origin groups, at
6.3%. The uninsured rates for Blacks and Asians were higher
than for non-Hispanic Whites, at 10.5% and 7.6%, respectively.
Hispanics had the highest uninsured rate, at 16.0%.”35 In the No
Screeningscenario,Hispanicsmayhave lowermedical costsbut
they would have higher rates of premature death (higher pro-
ductivity losses) due to untreated cardiac and digestive condi-
tions. In the No Screening scenario, there could be inadequate
follow-up for women who are symptomatic or in the in-
determinate phase if they are uninsured and, particularly, if they
are undocumented and fear deportation.
Because benznidazole has been approved for commercial
sale in the United States, it will eventually mean additional costs
TABLE 6
Implementation costs: targeted and universal screening
Targeted (480,000 births) Universal (4 million births)
At $60 per screen At $8 per screen At $60 per screen At $8 per screen
Maternal screening $28,800,000 $3,840,000 $240,000,000 $32,000,000
Newborn testing (6,300 × $400) $2,520,000 $2,520,000 $2,520,000 $2,520,000
Additional monitoring for mothers,
indeterminate phase 4,400 mothers ×
$5,495
$24,178,000 $24,178,000 $24,178,000 $24,178,000
Additional cardio monitoring for mothers,
digestive symptoms 600 mothers ×
$12,250
$7,350,000 $7,350,000 $7,350,000 $7,350,000
Total implementation cost $62,848,000 $37,888,000 $274,048,000 $66,048,000
1740 STILLWAGGON AND OTHERS
for the Screening option. It would be speculative at this time to
choose aprice to include in the analysis.Weexpect that the cost
will not be exorbitant, given that the FDA-approved product is
made by a company that has a corporate social responsibility
partner devoted to access to treatment of Chagas disease
(https://www.dndi.org/2016/media-centre/press-releases/
partnership-register-benzindazole-usa-latinamerica/).
It is projected that successful domestic vector control
programs in endemic areas of Latin America and prenatal
screening programs would ultimately obviate the need for the
proposed program.1 It is, in the best case, a self-limiting
program. This model, then, does not represent longer term
future costs because Chagas disease could be virtually
eliminated in human populations. A strategy to speed up that
process would include a test-and-treat program for young
Hispanics from endemic areas. Treating young women before
pregnancy can reduce their own morbidity and prevent
transmission to future children.19,20 Treating young men for
their own future health would be ethically appropriate as well.
CONCLUSION
Maternal screening, along with infant testing and maternal
and infant treatment as indicated, has the potential to reduce
disability and death fromChagas disease in the United States
substantially. Cost savings from a societal perspective from
such a program would be outstanding, and the results are
robust across a wide range of prevalence, rates of mother-to-
child transmission, and screening costs, as well as all other
clinical and cost parameters. Sensitivity analysis in our model
demonstrates that, even at current testing costs, maternal
screening and follow-up infant testing and treatment as in-
dicated is cost saving for maternal prevalence as low as
0.057% and for mother-to-child transmission probability as
low as 0.001%. With the new point-of-care test, universal
screening is cost saving for prevalence as low as 0.008% of
pregnant women. The human and economic cost of Chagas
disease is very great, even in a country with low prevalence
and low transmission. Lifetime societal costs, including direct
medical costs and productivity loss due to morbidity and
premature mortality, are nearly 10 times the cost of imple-
mentingauniversalmaternal screeningprogram. This analysis
supports adding testing for T. cruzi infection to routine screening
in pregnancy or at the time of birth in the United States.
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